<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349190</url>
  </required_header>
  <id_info>
    <org_study_id>0001</org_study_id>
    <nct_id>NCT03349190</nct_id>
  </id_info>
  <brief_title>Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques</brief_title>
  <acronym>NACRE</acronym>
  <official_title>A Retrospective, National, Multicenter Study Evaluating the Impact of Ulipristal Acetate (Esmya®) on Infertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques (ART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gedeon Richter Plc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibroid is a frequent pathology of infertile women. Its deleterious effect on the infertility
      would be due to the mechanical way.

      The interest of the resection of intramural fibroids is discussed. It is necessary to measure
      the indication of a myomectomy, whatever the surgical procedure. On the one hand, it may
      cause important potential complications, and on the other hand, the surgery does not improve
      the parameters of the fertility.

      Thus, it is a major stake to avoid the surgical operation. A decrease of the size of these
      fibroids by medical treatment is then a good option.

      When the surgical treatment is necessary, a medical pre-surgical treatment is often proposed
      in order to decrease the symptomatology and to reduce the size of the fibroid to facilitate
      the surgery.

      Acetate Ulipristal (UPA) has been marketed in this indication. Following the Pearl I-II
      studies, the first indication in France was a pre-surgical treatment for 3 months at a dose
      of 5 mg per day.

      The Pearl III and IV studies evaluated the Esmya® administration as a long-term intermittent
      repeated treatment, giving to it a prominent position for the long-term management of
      symptomatic fibroids.

      Furthermore, cases of pregnancy before surgery are frequently described in women with
      fibroids treated by UPA for a pre-IVF surgery.

      5 to 10 % of women who are managed for infertility have fibroids and only 2% to 3% have this
      unique cause of infertility.

      Then, some of patients followed in ART centers have been treated by UPA to reduce the
      fibroids size and/or to decrease the associate symptoms.

      The aim of this study is to evaluate in the different French ART centers, the impact on
      fertilization of UPA administration for infertile women with fibroids and to describe the
      modalities of its prescriptions and to collect information regarding safety tolerance profile
      of Esmya® in this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective, national, multicenter study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>15 days</time_frame>
    <description>Clinical pregnancy rate after maximum 4 embryos transferred by IVF/ICSI procedures ; pregnancy is defined by beta-hCG&gt; 1000 or presence of a gestation sac</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous pregnancy</measure>
    <time_frame>at least 2 months</time_frame>
    <description>Spontaneous pregnancy rate before first embryo transferred by IVF/ICSI procedures; pregnancy is defined by beta-hCG &gt; 1000 or presence of a gestation sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth / miscarriage</measure>
    <time_frame>9 months</time_frame>
    <description>Live birth rate / miscarriage rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroids size</measure>
    <time_frame>Baseline (before ulipristal acetate administration) and 20 months</time_frame>
    <description>Fibroids size reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery rate</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery description</measure>
    <time_frame>3 months</time_frame>
    <description>Description of the surgery type and surgery indication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of ulipristal acetate prescription</measure>
    <time_frame>20 months</time_frame>
    <description>Reasons of the prescription, type of fibroids concerned, number of cycles of treatment, treatment duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety impact on ulipristal acetate administration</measure>
    <time_frame>20 months</time_frame>
    <description>Review of adverse drug reactions resulting in ulipristal acetate treatment modification or discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulipristal acetate safety analysis in infertile women with fibroids</measure>
    <time_frame>20 months</time_frame>
    <description>Review of all serious adverse reactions (expected or unexpected) in this population</description>
  </secondary_outcome>
  <enrollment type="Anticipated">289</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Fibroid Uterus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ULIPRISTAL ACETATE</intervention_name>
    <description>Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infertile women with fibroids managed with assisted reproduction techniques (ART)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 to 43 years 'old at the time of the beginning of ulipristal acetate
             intake

          2. Women with fibroid at the time of ulipristal acetate prescription

          3. Women with desire to have children and managed for infertility in an ART center
             (whatever the type of infertility treatment)

          4. Women having received a treatment by ulipristal acetate

        6) Data collected between 2013/12/01 and 2018/06/30 ; data collected between ulipristal
        acetate prescription until the term of pregnancy or embryo transfer failure (up to 4) or
        death/lost to follow up or ART treatment discontinuation

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine RONGIERES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ADEFIV &amp; University Hospitals of Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine RONGIERES, MD</last_name>
    <phone>+33 369553456</phone>
    <email>catherine.rongieres@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle BACK, Pharm D</last_name>
    <phone>+33 662509534</phone>
    <email>christelle.back@expertiserc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Emmanuel BOUET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale LAGRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude HOCKE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Creteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire PIETIN-VIALLE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Val D'Ouest</name>
      <address>
        <city>Ecully</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine CHOMIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géraldine GIRAUDET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cpma Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline BOTTIN-DUBERGE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imr Rocca</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre FRANQUEBALME</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chevalier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas CHEVALIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Caremeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie HUBERLANT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH TENON</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle MATHIEU D'ARGENT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternite Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire GAUCHE-CAZALIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Royal - Chirurgie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pietro SANTULLI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cmco - University Hospitals of Strasbourg</name>
      <address>
        <city>Schiltigheim</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine RONGIERES, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Territorial Gaston Bourret</name>
      <address>
        <city>Nouméa</city>
        <country>New Caledonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clotilde DECHANET, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>New Caledonia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO</investigator_affiliation>
    <investigator_full_name>Catherine Rongieres</investigator_full_name>
    <investigator_title>Head of the ART center of the University Hospital of Strasbourg</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

